Company Filing History:
Years Active: 2001-2005
Title: Innovator Spotlight: Barbara Mroczkowski
Introduction
Barbara Mroczkowski is an accomplished inventor based in Encinitas, California, renowned for her impactful contributions to the field of biotechnology. With a total of five patents to her name, she has made significant strides in understanding key biological processes vital for developing therapeutic interventions.
Latest Patents
One of Mroczkowski's latest patents involves the "Modifications of the VEGF receptor-2 protein and methods of use." In this innovation, a 2.4 Å crystal structure of a protein construct containing the catalytic kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2/KDR) has been determined in an unliganded, phosphorylated state. This protein construct features a modified catalytic linker that exhibits comparable in vitro kinase activity to constructs containing the entire KID. More importantly, this development allows for complete crystallization of the protein, enabling characterization through X-ray crystallography. The invention further details the application of X-ray crystallographic data for identifying and constructing potential therapeutic compounds aimed at treating various disease conditions.
Career Highlights
Mroczkowski has established herself as a key player in her domain, working primarily at Agouron Pharmaceuticals, Inc. Her research focuses on angiogenesis and the specific mechanisms involved in vascular endothelial growth factor signaling. Her expertise has been instrumental in pioneering novel approaches for drug development.
Collaborations
Throughout her career, Mroczkowski has collaborated with esteemed colleagues, including Michele Ann McTigue and Chris Pinko. These partnerships have contributed to her success in advancing scientific knowledge and bringing innovative solutions to the pharmaceutical industry.
Conclusion
Barbara Mroczkowski stands out as a leading inventor in the field of biotechnology, with her patents playing a crucial role in understanding disease mechanisms and advancing therapeutic options. Her work at Agouron Pharmaceuticals, combined with her collaborative efforts, underscores her commitment to driving innovation in healthcare.